HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PRM-151

recombinant human serum amyloid P/pentraxin 2 for the treatment of fibrosis

Networked: 9 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	van den Blink, Bernt: 2 articles (01/2019 - 03/2016)
2.	Bose, Prithviraj: 2 articles (01/2018 - 01/2017)
3.	Verstovsek, Srdan: 2 articles (01/2018 - 01/2017)
4.	Antin-Ozerkis, Danielle E: 1 article (01/2019)
5.	Aubin, Francois: 1 article (01/2019)
6.	Brown, A Whitney: 1 article (01/2019)
7.	Golden, Jeffrey A: 1 article (01/2019)
8.	Gupta, Renu: 1 article (01/2019)
9.	Hamblin, Mark J: 1 article (01/2019)
10.	Ho, Lawrence A: 1 article (01/2019)

Related Diseases

1.	Fibrosis (Cirrhosis) 03/01/2016 - "PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibrosis in preclinical lung fibrosis models, and was well tolerated with a favourable pharmacokinetic profile in an earlier single-dose phase I study.A randomised, double-blind, placebo-controlled, multiple ascending dose trial was performed to assess the tolerability and pharmacokinetic and pharmacodynamic characteristics of multiple doses of PRM-151 in IPF patients. " 12/01/2013 - "PRM-151, recombinant human Pentraxin-2 (PTX-2) also referred to as serum amyloid P (SAP), is under development for treatment of fibrosis. " 06/01/2010 - "PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis."
2.	Anemia 01/01/2017 - "First-in-class agents such as the activin receptor IIA ligand trap sotatercept (for anemia of MF), the telomerase inhibitor imetelstat, and the antifibrotic agent PRM-151 (recombinant human pentraxin-2) are also in clinical trials. " 12/01/2022 - "This review summarizes current and emerging treatments for anemia in MF, including luspatercept and KER-050 (transforming growth factor-β ligand traps), momelotinib and pacritinib (JAK inhibitors), pelabresib (a bromodomain extra-terminal domain inhibitor), PRM-151 (an antifibrotic agent), imetelstat (a telomerase inhibitor), and navitoclax (a BCL-2/BCL-xL inhibitor). "
3.	Corneal Injuries 11/01/2011 - "PRM-151 inhibits myofibroblast generation when administered by sub-conjunctival injection, but not when administered topically, after opacity-producing corneal injury. " 11/01/2011 - "This study investigated whether PRM-151 (Promedior, Inc., Malvern, PA), a recombinant form of human pentraxin-2 (PTX-2, also referred to as serum amyloid P, hSAP), that inhibits differentiation of circulating monocytes into fibrocytes and profibrotic macrophages, could modulate generation of myofibroblasts after opacity-producing corneal injury in rabbits, and, therefore, have potential to reduce or prevent haze after PRK. "
4.	Primary Myelofibrosis (Myelosclerosis) 06/01/2014 - "Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis. "
5.	Idiopathic Pulmonary Fibrosis 01/01/2019 - "Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a recombinant human pentraxin 2 protein, in a phase 2 double-blind, randomised controlled trial had significantly reduced decline in percentage of predicted forced vital capacity (FVC) and stabilised 6-min walking distance compared with placebo over a 28-week period. "

Related Drugs and Biologics

1.	Amyloid (Amyloid Fibrils)
2.	Telomerase (Telomerase Reverse Transcriptase)
3.	Ligands
4.	imetelstat
5.	Activin Receptors (Activin Receptor)
6.	Proteins (Proteins, Gene)
7.	ACE-011
8.	ruxolitinib
9.	Transforming Growth Factors (Transforming Growth Factor)
10.	Janus Kinase Inhibitors